AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy

Sex difference in the development of hepatocellular carcinoma after direct‐acting antiviral therapy in patients with HCV infection

(2020) Takao Watanabe et al.   JOURNAL OF MEDICAL VIROLOGY

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation

(2019) Tatsuo Kanda et al.   Hepatology International

Hepatocellular carcinoma

(2018) Alejandro Forner et al.   LANCET

Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group

(2018) Toshie Mashiba et al.   PLoS One

Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis

(2018) Maria Guarino et al.   DIGESTIVE AND LIVER DISEASE

Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection

(2018) Elisabetta Degasperi et al.   Clinical Gastroenterology and Hepatology

Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection

(2018) Takao Watanabe et al.   HEPATOLOGY RESEARCH

The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy

(2018) Yuko Nagaoki et al.   JOURNAL OF MEDICAL VIROLOGY

Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C

(2017) Hiroko Nagata et al.   JOURNAL OF HEPATOLOGY

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression

(2017) Reem Waziry et al.   JOURNAL OF HEPATOLOGY

Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

(2016) S. Petta et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals

(2016) Fabio Conti et al.   JOURNAL OF HEPATOLOGY

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy

(2016) María Reig et al.   JOURNAL OF HEPATOLOGY

Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy

(2014) Naoki Hiramatsu et al.   HEPATOLOGY RESEARCH

Post-treatment Levels of α-Fetoprotein Predict Incidence of Hepatocellular Carcinoma After Interferon Therapy

(2013) Tsugiko Oze et al.   Clinical Gastroenterology and Hepatology

α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C

(2013) Yasuhiro Asahina et al.   HEPATOLOGY

Validation and limitation of age-period-cohort model in simulating mortality due to hepatocellular carcinoma from 1940 to 2010 in Japan

(2013) Tomoyuki Akita et al.   HEPATOLOGY RESEARCH

Novel therapies for hepatitis C — one pill fits all?

(2013) Michael P. Manns et al.   NATURE REVIEWS DRUG DISCOVERY

Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma

(2012) Hashem B. El-Serag   GASTROENTEROLOGY

Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C

(2012) Yasuji Arase et al.   HEPATOLOGY